Zur Rose Group: Purchase price payment for medpex acquisition completed early by earn-out settlement

EQS Group-News: Zur Rose Group AG / Key word(s): Financing
27.12.2019 / 07:00

Press release

medpex acquisition:
- Puchase price payment completed early by earn-out settlement
- medpex founders take on leading management positions in Germany segment
- Best-in-class skills at medpex drive ahead growth in market leadership in Germany

The Zur Rose Group and the sellers of the medpex online pharmacy activities have agreed to settle the 2019 and 2020 earn-out components, which form part of the purchase price, at the end of 2019 by making a one-off payment of the amount estimated in the 2019 interim financial statements. Since the takeover the founders of medpex have driven ahead the business successfully and reached the agreed growth targets. medpex has best-in-class skills in online marketing and technology and forms the ideal complement to the current strategy and focus on the German market to expand market leadership.

By ending the earn-out early the Zur Rose Group aims to use the expertise of the founders as quickly as possible for the entire Germany segment. They are therefore taking on leading management positions in the Germany segment. To tie them in to the Zur Rose Group they participate in a management share programme on a considerable scale and will significantly increase their existing holdings.

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda
22 January 2020 Sales 2019
19 March 2020 2019 Full-Year Results
16 April 2020 First Quarter Trading Update
23 April 2020 Annual General Meeting

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management and actively promotes its positioning as a comprehensive, integrated cross-service healthcare platform. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, payers and industry.

The Zur Rose Group is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. The company employs over 1,300 people at various locations and generated a turnover of CHF 1,207 million in the 2018 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). Further information at zurrosegroup.com

End of Corporate News